Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized withdrawal study of abrocitinib in moderate-to-severe atopic dermatitis
MOH_2019-01-08_003597Phase 3Completed
- Sponsor
- Pfizer
- Start
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of abrocitinib in atopic dermatitis (AD) (5 arms), sponsored by Pfizer. Primary endpoint: Maintenance of response. Started Nov 2018; status: completed.
02
Drugs
abrocitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on MOH_2019-01-08_003597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-01-08_003597.